## 5 Conclusions  
We demonstrated that by using a minimal subset of radiomics features, the performance achieved showed significant promise, with an AUC of 86.9%, for predicting _EGFR_ mutation status. Our findings underscore the promising potential of radiomics features as non-invasive predictive imaging biomarkers for _EGFR_ mutation status, which may improve personalized treatment in NSCLC. Additionally, radiomics may be a useful non-invasive option for patients for whom biopsy is technically challenging and for patients with inadequate tumor tissue for the detection of _EGFR_ mutations. Radiomics may serve as a non-invasive approach that can be used in the identification of _EGFR_ mutation in NSCLC, considering the results of our study and previous studies. However, in order to verify the clinical value of radiomics in NSCLC, additional studies are required.  
While our study showed considerable promise, it also has several limitations that need to be taken into consideration. First, while the provisional dataset contained 1243 patients, the analysis only focused on 420 of them without using any external validation set. Despite our promising results, the evaluation of a larger cohort of NSCLC patients whose _EGFR_ status has been determined would be beneficial. Lastly, further studies could explore how this radiogenomic model could be applied to more comprehensive genotypes, like _EGFR_-TKI sensitivity or exon levels. However, this study is planned for the future due to a decrease in the number of patients.  
Another study limitation is the absence of external validation. While our model performed well internally, it has not yet been validated on external datasets. Futurework will address this by incorporating a multicenter study with a broader range of mutations, including \(EGFR\)-TKI sensitivity and exon-specific mutations. This step is crucial to confirming the generalizability and clinical utility of our radiomics model. This reduction may impact the overall statistical power of this study, and future work will involve larger datasets to validate the findings.  
Conceptualization, A.K.C., E.B.K., E.U.B., S.A. and S.D.S.; Methodology, A.K.C., K.O. and A.G.C.; Validation, E.B.K., K.O., E.G. and Y.K.; Formal analysis, K.O.; Investigation, A.K.C., H.O., A.G.C. and Y.K.; Resources, F.I.; Data curation, E.B.K., K.O., H.O., A.G.C., E.G., Y.K., F.I. and E.U.B.; Writing--original draft, A.K.C. and E.B.K.; Writing--review & editing, A.K.C., H.O., S.A. and S.D.S.; Supervision, A.K.C. All authors have read and agreed to the published version of the manuscript.  
This research received no external funding.  
The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Ankara University Faculty of Medicine (AUFM) (approval number: I2-97-21 and date of approval: 11.02.2021).  
The study protocol was approved by the Institutional Review Board of Ankara University Faculty of Medicine (AUFM) (no: I2-97-21), thus removing the need to seek informed consent.  
The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.  
The authors declare no conflict of interest.